China approves clinical trials for CanSino's inhaled COVID-19 vaccine
BEIJING -- China's drug authority has approved clinical tests for an inhaled COVID-19 vaccine co-developed by domestic company CanSino Biologics, the Agence France-Presse (AFP) reported on Tuesday.
The clinical trial application of the vaccine, jointly developed by CanSino and the Beijing Institute of Biotechnology, was approved by the National Medical Products Administration (NMPA) on Monday, the pharmaceutical firm said in a filing on the Hong Kong stock exchange on Tuesday.
The safety and efficacy of the inhaled vaccine remain "subject to confirmation," the firm said.
The NMPA conditionally approved a recombinant vaccine for COVID-19 made by CanSino last month, which marked the first approved adenoviral vector vaccine for COVID-19.
More than 85.85 million doses of COVID-19 vaccines have been administered across China as of Wednesday, the National Health Commission said Thursday.
- China ramping up Nipah virus surveillance
- Shanghai to host embodied intelligence expo in July
- Chongqing sets GDP growth target of over 5% for 2026
- Xinjiang strengthens economic, cultural ties with Hong Kong, Macao
- Former senior political adviser sentenced to 12 years for bribery
- Hubei's government becomes first in China to add 'emotional value' to work report
